TIMI

TIMI or Thrombolysis in Myocardial Infarction is a clinical trial group funded by the National Heart, Lung, and Blood Institute to investigate the treatment of acute myocardial infarction. This group has conducted several large, multicenter trials that have led to changes in medical guidelines and practice.

History

The TIMI Study Group was established in 1984 at the Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, to conduct the original TIMI Trial. The group has since grown to include over 50 clinical research professionals and has conducted over 50 clinical trials involving more than 200,000 patients worldwide.

TIMI Score

The TIMI Score is a tool used by healthcare professionals to assess the risk of death and ischemic events in patients with unstable angina or non-ST elevation myocardial infarction. The score is based on seven variables, each of which is associated with an increased risk of adverse outcomes. The higher the TIMI Score, the greater the risk.

TIMI Trials

The TIMI Trials have investigated a variety of treatments for acute myocardial infarction, including thrombolytic therapy, antiplatelet therapy, anticoagulant therapy, and invasive strategies. The results of these trials have informed the development of guidelines for the treatment of acute myocardial infarction.

See Also

• Myocardial Infarction
• Thrombolysis
• Clinical Trials

References

<references />

External Links

• TIMI Study Group Official Website

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia